Gerlach, M.

Parkinson’s Disease and Related Disorders

Gerlach, M. - Parkinson’s Disease and Related Disorders, ebook


Ebook, PDF with Adobe DRM
ISBN: 9783211452950
DRM Restrictions

PrintingNot allowed
Copy to clipboardNot allowed

Table of contents

1. Melvin Yahr (1917–2004). An appreciation
C. Powell

2. Melvin D. Yahr, 1917–2004. A personal recollection
H. Kaufmann

1.. Pathology

3. The discovery of dopamine deficiency in the parkinsonian brain
O. Hornykiewicz

4. Synchronizing activity of basal ganglia and pathophysiology of Parkinson’s disease
G. Heimer, M. Rivlin, Z. Israel, H. Bergman

5. Basal ganglia discharge abnormalities in Parkinson’s disease
T. Wichmann, M. R. DeLong

6. Bad oscillations in Parkinson’s disease
P. Brown

7. Cortical muscle coupling in Parkinson’s disease (PD) bradykinesia
M. J. McKeown, S. J. Palmer, W.-L. Au, R. G. McCaig, R. Saab, R. Abu-Gharbieh

8. GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons
R. E. Burke

9. The engrailed transcription factors and the mesencephalic dopaminergic neurons
D. Gherbassi, H. H. Simon

10. The role of Pitx3 in survival of midbrain dopaminergic neurons
S. M. Smits, M. P. Smidt

11. Genetic analysis of dopaminergic system development in zebrafish
S. Ryu, J. Holzschuh, J. Mahler, W. Driever

12. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease
A. Y. Deutch

13. The nigrostriatal DA pathway and Parkinson’s disease
K. Fuxe, P. Manger, S. Genedani, L. Agnati

14. Relationship between axonal collateralization and neuronal degeneration in basal ganglia
M. Parent, A. Parent

15. Pathology associated with sporadic Parkinson’s disease — where does it end?
H. Braak, C. M. Müller, U. Rüb, H. Ackermann, H. Bratzke, R. A. I. Vos, K. Tredici

16. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease
G. M. Halliday, K. Tredici, H. Braak

17. A short overview on the role of a-synuclein and proteasome in experimental models of Parkinson’s disease
F. S. Giorgi, A. Bandettini di Poggio, G. Battaglia, A. Pellegrini, L. Murri, S. Ruggieri, A. Paparelli, F. Fornai

18. The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?
S. Gispert-Sanchez, G. Auburger

2.. Iron and neuromelanin

19. New face of neuromelanin
K. L. Double, G. M. Halliday

20. The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells
W. Maruyama, M. Shamoto-Nagai, Y. Akao, P. Riederer, M. Naoi

21. Potential sources of increased iron in the substantia nigra of parkinsonian patients
M. Gerlach, K. L. Double, M. B. H. Youdim, P. Riederer

22. Iron and Friedreich ataxia
M. Pandolfo

3.. Genetics

23. Nongenetic causes of Parkinson’s disease
A. R. Chade, M. Kasten, C. M. Tanner

24. Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?
A. Lannuzel, G. U. Höglinger, P. Champy, P. P. Michel, E. C. Hirsch, M. Ruberg

25. CYP450, genetics and Parkinson’s disease: gene × environment interactions hold the key
G. D. Mellick

26. Unique cytochromes P450 in human brain: implication in disease pathogenesis
V. Ravindranath, R. P. Kommaddi, H. V. Pai

27. Cytochrome P450 and Parkinson’s disease: protective role of neuronal CYP 2E1 from MPTP toxicity
C. Viaggi, C. Pardini, F. Vaglini, G. U. Corsini

28. Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease
S. Miksys, R. F. Tyndale

29. Genetic causes of Parkinson’s disease: extending the pathway
O. Riess, R. Krüger, H. Hochstrasser, A. S. Soehn, S. Nuber, T. Franck, D. Berg

30. Progress in familial Parkinson’s disease
Y. Mizuno, N. Hattori, H. Yoshino, Y. Hatano, K. Satoh, H. Tomiyama, Y. Li

31. Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins
N. Hattori, Y. Machida, S. Sato, K. Noda, M. Iijima-Kitami, S. Kubo, Y. Mizuno

32. Parkin and defective ubiquitination in Parkinson’s disease
T. M. Dawson

33. PINK-1 and DJ-1 — new genes for autosomal recessive Parkinson’s disease
P. Heutink

34. Clinical and pathologic features of families with LRRK2-associated Parkinson’s disease
N. R. Whaley, R. J. Uitti, D. W. Dickson, M. J. Farrer, Z. K. Wszolek

35. Molecular genetic findings in LRRK2 American, Canadian and German families
T. Gasser

4.. Imaging

36. Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort
C. -S. Lu, Y. -H. Wu Chou, Y. -H. Weng, R. -S. Chen

37. Neuroimaging in Parkinson’s disease
W. Lokau, J. R. Adams, A. Troiano, A. J. Stoessl

38. Transcranial sonography in the early and differential diagnosis of Parkinson’s disease
D. Berg

5.. Models

39. How to judge animal models of Parkinson’s disease in terms of neuroprotection
E. C. Hirsch

40. Limitations of cellular models in Parkinson’s disease research
B. H. Falkenburger, J. B. Schulz

41. The Rotenone model of Parkinsonism — the five years inspection
G. U. Hoöglinger, W. H. Oertel, E. C. Hirsch

42. Controversies on new animal models of Parkinson’s disease Pro and Con: the rotenone model of Parkinson’s disease (PD)
W. J. Schmidt, M. Alam

43. Proposed animal model of severe Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum
R. M. Kostrzewa, J. P. Kostrzewa, R. Brus, R. A. Kostrzewa, P. Nowak

44. a-Synuclein overexpression model
H. Mochizuki, M. Yamada, Y. Mizuno

45. Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies
H. Németh, J. Toldi, L. Vécsei

6.. Clinical approaches

46. What’s new? Clinical progression and staging of Parkinson’s disease
C. G. Goetz

47. Parkinson’s disease: premotor clinico-pathological correlations
E. Ch. Wolters, H. Braak

48. Detection of preclinical Parkinson’s disease along the olfactory trac(t)
H. W. Berendse, M. M. Ponsen

49. The clinical approach to gait disturbances in Parkinson’s disease; maintaining independent mobility
N. Giladi, Y. Balash

50. Getting around and communicating with the environment: visual cognition and language in Parkinson’s disease
I. Bodis-Wollner, M. -Y. Jo

51. Cardiovascular aspects of Parkinson disease
D. S. Goldstein

52. Multiple system atrophy and autonomic failure
C. J. Mathias

53. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview
C. L. Comella

54. Sleep and wakefulness disturbances in Parkinson’s disease
I. Arnulf

7.. Neuroinflammation

55. Parkinson’s disease dementia: what’s in a Lewy body?
D. J. Burn

56. Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10
L. Qian, J. -S. Hong, P. M. Flood

57. Role of cytokines in inflammatory process in Parkinson’s disease
M. Sawada, K. Imamura, T. Nagatsu

8.. Neurosurgery

58. Surgical therapy for Parkinson’s disease
A. L. Benabid, S. Chabardès, E. Seigneuret, V. Fraix, P. Krack, P. Pollak, R. Xia, B. Wallace, F. Sauter

59. Deep brain stimulation for the treatment of Parkinson’s disease
C. Hamani, J. Neimat, A. M. Lozano

60. Deep brain stimulation in Parkinson’s disease patients: biochemical evidence
A. Stefani, E. Fedele, S. Galati, M. Raiteri, O. Pepicelli, L. Brusa, M. Pierantozzi, A. Peppe, A. Pisani, G. Gattoni, A. H. Hainsworth, G. Bernardi, P. Stanzione, P. Mazzone

61. Neurosurgery in Parkinson’s disease: the doctor is happy, the patient less so?
Y. Agid, M. Schüpbach, M. Gargiulo, L. Mallet, J. L. Houeto, C. Behar, D. Maltête, V. Mesnage, M. L. Welter

9.. L-Dopa

62. Placebo effect and dopamine release
R. Fuente-Fernández, S. Lidstone, A. J. Stoessl

63. A new look at levodopa based on the ELLDOPA study
S. Fahn

64. Thirty five years of experience in the treatment of Parkinson’s disease with levodopa and associations
C. Chouza, R. Buzó, A. Scaramelli, S. Romero, O. Medina, R. Aljanati, E. Dieguez, N. Lisanti, J. Gomensoro

10.. Neuroprotection

65. Concerning neuroprotective therapy for Parkinson’s disease
R. J. Uitti, Z. K. Wszolek

66. Triggering endogenous neuroprotective mechanisms in Parkinson’s disease: studies with a cellular model
M. J. Zigmond

67. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression
M. Weinstock, L. Luques, C. Bejar, S. Shoham

68. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease
S. Gal, M. Fridkin, T. Amit, H. Zheng, M. B. H. Youdim

69. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety
O. Weinreb, T. Amit, O. Bar-Am, Y. Sagi, S. Mandel, M. B. H. Youdim

11.. Other treatment strategies

70. Anti-apoptotic gene therapy in Parkinson’s disease
J. B. Schulz

71. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors
H. Kaufmann

12.. Dystonia

72. Pathophysiology of dystonia
M. Hallett

73. Genetics of dystonia
S. Bressman


Printing: not available
Clipboard copying: not available

Keywords: MEDICAL / Public Health MED078000

Publication year
Medicine, Health Care, Mode

Similar titles